Your browser doesn't support javascript.
loading
Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer / Journal of the Korean Cancer Association, 대한암학회지
Article in En | WPRIM | ID: wpr-719415
Responsible library: WPRO
ABSTRACT
Epidermal growth factor receptor (EGFR)‒tyrosine kinase inhibitors (TKIs) are effective clinical therapeutics for EGFR-mutant non-small cell lung cancer (NSCLC). Osimertinib, a thirdgeneration EGFR TKI, has proven effective against T790M mutations. However, the vast majority of patients acquire resistance following successful treatment. A 59-year-old female patient with metastatic NSCLC developed resistance after 43 weeks of osimertinib. CancerSCAN of the metastatic liver lesion revealed a EGFR C797G mutation at an allele frequency of 72%, a preexisting T790M mutation (73%) in cis and an exon 19 deletion (87%). Another 53-year-old female patient developed systemic progression after 10 months of osimertinib. CancerSCAN of the lung biopsy identified an EGFR L718Q mutation at an allele frequency of 7%, concomitant PIK3CA E545K (12.90%) and preexisting EGFR L858R (38%), but loss of the T790M mutation. The heterogeneity of osimertinib resistance mechanisms warrants further investigation into novel or combination agents to overcome the rare acquired resistances.
Subject(s)
Key words
Full text: 1 Index: WPRIM Main subject: Phosphotransferases / Population Characteristics / Biopsy / Exons / Carcinoma, Non-Small-Cell Lung / ErbB Receptors / Gene Frequency / Liver / Lung Type of study: Prognostic_studies Limits: Female / Humans Language: En Journal: Cancer Research and Treatment Year: 2019 Type: Article
Full text: 1 Index: WPRIM Main subject: Phosphotransferases / Population Characteristics / Biopsy / Exons / Carcinoma, Non-Small-Cell Lung / ErbB Receptors / Gene Frequency / Liver / Lung Type of study: Prognostic_studies Limits: Female / Humans Language: En Journal: Cancer Research and Treatment Year: 2019 Type: Article